soul trial oral semaglutide cardiovascular outcomes 2024 results nejm reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 ๐ธ๐ช #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Trial Scorecard: SOUL
Pay in 4 interest-free payments of $6.83 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Jul 31 - Aug 5

























